Determining the frequency of extramedullary disease when using chemotherapy, AZA alone, or AZA + venetoclax in the C1498 AML model could reveal additional benefits of using BCL-2 inhibitors in combination with HMAs. Here, BCL2 is linked to acute myeloid leukemia.